Archive for the ‘Pharmaceuticals’ Category

Just some of the over 700,000 signature delivered to Mylan

Just some of the over 700,000 signature delivered to Mylan, Photo Credit: Ed Grystar W. PA. Coalition for Single Payer Healthcare

By Sean Grant

Protesters on Tuesday delivered petitions to Mylan’s corporate headquarters just outside of Pittsburgh demanding that the company end price gouging EpiPen users, they did not expect a warm welcome. They knew beforehand that they would not be allowed to approach the building. In front of TV cameras, Mylan accepted the petitions on a wheeled cart.

But Mylan representatives who collected the petition signatures – gathered by Public Citizen, MoveOn.org Civic Action and others – offered no comment to the media, raising the question of whether the company will heed the call of the nearly 700,000 Americans who signed the petitions. The public clearly is outraged at Mylan’s raising the price of EpiPens by more than 500 percent since 2007 for no apparent reason other than greed.

Protesters were not allowed to enter Mylan's visitor entrance at their building

Protesters were not allowed to enter Mylan’s visitor entrance, Photo Credit: Ed Grystar W. PA. Coalition for Single Payer Healthcare

Before the petition delivery, Mylan twice announced new measures to appease the public, but these weak attempts at appearing contrite only further enraged people. As Public Citizen President Robert Weissman stated, “It’s not enough to offer coupons and it’s not enough to offer an overpriced generic version of its own branded product. The company must roll back its unjustified and outrageous price increases.” Read those press releases here and here.

As the petitions were rolled away on dollies to chants of “people over profit,” attention shifted to Mike Laffin, a member of Mylan’s communications team, who was sent out to deal with the reporters clamoring to ask questions. Laffin, however, could provide nothing more substantive than “Any other questions need to be directed to our communications team or customer service.” He repeated the phrase several times, perhaps most forcefully when one reporter asked if Mylan had any plans to lower the price of the EpiPen further.

Considering how ineffective the customer service department has been so far, referring reporters to it – by a live person from the communications department – doesn’t seem like the brightest PR move. But the company keeps making missteps, it seems. It is imperative Mylan finally listen and take substantive action.

View a video of the petition delivery 

 

By Anisha Sehgal

Both consumers and healthcare payers are struggling with the rising price of drugs. Unless meaningful reforms are enacted, this problem will only get larger and patients will continue to face crippling out-of-pocket costs in order to care for themselves and their loved ones. The Medicare Part B demonstration is an example of such a reform and would begin to repair the dysfunctional way that we pay for prescription drugs. Unfortunately for patients, the pharmaceutical industry has mounted considerable opposition to this reform and it is not alone. Politicians and organizations such as patients’ groups have also voiced their objection. However, the majority of these individuals and groups have received industry funding.

A recent Public Citizen report revealed that of the 147 patients’ groups who have signed letters objecting to the Medicare Part B demonstration at least 110 (75%) received funding from pharmaceutical or medical device corporations. Since patients’ groups are not required to disclose their funding sources there may be even more than the 110 groups identified by the report that received money from pharma.

The letter organized by the Community Oncology Alliance was sent to congressional leadership while the letter organized by the Partnership to Improve Patient Care was sent to the Center for Medicare and Medicaid Services (CMS). Along with the 147 patients’ groups, 241 doctors’ groups and pharmaceutical industry groups — both of which benefit from the maintaining the status quo of the current reimbursement method — signed either of the two letters opposing the reform. The letters’ combination of patients’ groups as well as industry groups, such as local Biotechnology Innovation Organization (BIO) affiliates, demonstrates the close ties patients’ groups have with the pharmaceutical industry.

In 2015, Part B spending reached $22 billion, double the amount it was in 2007. A reform such as this is necessary in order to remedy Medicare Part B’s unsustainable spending trend. The Medicare Part B demonstration, which is supported by numerous consumer interest groups including Public Citizen, aims to remove incentives for doctors to unnecessarily prescribe higher priced medicines when effective and affordable alternatives are available. Currently a physician who administers a drug under Medicare Part B will be reimbursed for the average sales price plus six percent. The demonstration proposes changing the reimbursement to the average sales price plus 2.5 percent and a flat dollar amount.

The pharmaceutical industry is strongly opposed to this reform because a decrease in the prescription of higher-priced drugs means a decrease in the industry’s profits. In fact, the industry has already spent more than $9 million in campaign funding for members of Congress, which is strongly correlated with lawmakers’ stances on the issue, as revealed by another recent Public Citizen report.

The pharmaceutical industry’s troubling pattern of influence raises questions about the independence of this reform’s opponents. Patients’ groups should reconsider their stance on this issue and realize that in this debate pharma is only looking out for itself, not for the deserving patients of this country.

By Will Neer and Anisha Sehgal

Imagine being diagnosed with a life threatening illness. The immediate reactions of shock and panic may also be mixed with relief once your doctor informs you that there is an effective treatment available. However, that relief can quickly disappear and instead be replaced with hesitation and fear once the hefty price tag associated with the treatment is revealed.  This unfair cycle of emotions is a process too many Americans and their families are forced to experience due to astronomical drug prices.

A type of drug commonly used to treat serious illnesses is a biologic. However, as prescription drug corporations often charge more than $100,000 annually for biologic treatments, many Americans are fighting insurer rationing or even turning to pill splitting.  A piece of bipartisan legislation, S. 0394 / H.R. 5573, titled the Price, Relief, Innovation and Competition for Essential Drugs (PRICED) Act aims to remedy this problem. The PRICED Act would amend U.S. law and shorten the time that prescription drug corporations have monopolies on biologic medicines – and how long they can charge monopoly prices, thereby making these treatments more readily accessible.

Continue Reading

By Anisha Sehgal

Pharma Part B infographicDuring election season, Americans across the country hear politicians make grand statements on how they will look out for the good, hard-working people of their state and push for progress that will benefit us all. As we watch them head off to Washington we expect or at least hope that they will deliver on their promises and act in a manner that looks out for our best interests.

However, a recent Public Citizen report on the role of corporate money in politics has revealed the strong influence donations can have on swaying lawmakers’ support on big issues. We are in the midst of a contentious debate regarding the Centers for Medicare and Medicaid Services’ (CMS) proposed Medicare Part B demonstration, a proposal strongly opposed by the pharmaceutical industry. Public Citizen’s new study reveals that members of Congress who opposed or were critical of the reform on average received 82% more in campaign contributions for the 2016 election cycle from the pharmaceutical and health products industry than rank and file members who did not take a stance against the reform.

Continue Reading

By Emma Stockton

Last month, The International AIDS Society’s conference in Vancouver came to a close with an announcement that gave the global AIDS community great hope. In 2011, The United Nations had set a goal of treating 15 million people by 2015. That goal, once thought unrealistic, was reached 9 months early. Now more than 15 million people around the world living with HIV are receiving treatment.

On July 14, the United Nations announced the laudable goal of ending AIDS by 2030. As U.N. Secretary-General Ban Ki-moon said, “Ending the AIDS epidemic as a public health threat by 2030 is ambitious, but realistic, as the history of the past 15 years has shown.”

One major contingency for this goal that must be addressed is access to treatment. We have conclusive evidence that starting antiretroviral treatment as soon as a patient is diagnosed with HIV is proven to vastly improve patients’ health outcomes and prevent future transmission. We also know of a French teen born infected with HIV who received treatment until age 6 and has been virus free for twelve years.  This is the first confirmed long term remission for a child born with HIV.

However, despite the need to start treatment at diagnosis to be most effective, currently we are essentially rationing out ARVs to the sickest people because of their exorbitantly high cost. According to Medecins Sans Frontieres (MSF), more than half of the 37 million people living with HIV are not receiving treatment.

Continue Reading

© Copyright . All Rights Reserved.